

S6 Table. Subsequent treatment after disease progression

Treatment failure	Arm A (n=7)	Arm B (n=5)	Arm C (n=22)	Arm D (n=25)
Patients with treatment failure	6	5	18	15
Patients receiving subsequent therapy	6	4	15	12
Radiotherapy	0	0	3	2
Systemic chemotherapy	2	0	11	7
EGFR-TKI ^{a)}	2	4	1	1
Operation	0	0	0	2
Concurrent chemoradiotherapy	2	0	0	0

EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor. ^{a)}Two patients with *EGFR*-mutant tumor received EGFR-TKIs as third line treatment.